Role of afatinib in the treatment of advanced lung squamous cell carcinoma

Tiziana Vavalà ASL CN1, SC Oncologia, Ospedale Civile di Saluzzo, Saluzzo, Cuneo, Italy Abstract: Lung cancer treatment has considerably changed over the last few years: the identification of druggable oncogenic alterations and innovative immunotherapic approaches granted lung cancer pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Vavalà T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	lung cancer NSCLC squamous cell lung carcinoma afatinib EGFR TKI Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/837228eaa698435f878962933e6ea4e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:837228eaa698435f878962933e6ea4e8
record_format	dspace
spelling	oai:doaj.org-article:837228eaa698435f878962933e6ea4e82021-12-02T05:57:50ZRole of afatinib in the treatment of advanced lung squamous cell carcinoma1179-1438https://doaj.org/article/837228eaa698435f878962933e6ea4e82017-11-01T00:00:00Zhttps://www.dovepress.com/role-of-afatinib-in-the-treatment-of-advanced-lung-squamous-cell-carci-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Tiziana Vavalà ASL CN1, SC Oncologia, Ospedale Civile di Saluzzo, Saluzzo, Cuneo, Italy Abstract: Lung cancer treatment has considerably changed over the last few years: the identification of druggable oncogenic alterations and innovative immunotherapic approaches granted lung cancer patients the possibility of more efficient and less toxic therapeutic options than chemotherapy. Nowadays, lung squamous cell carcinomas (SqCCs) patients have the chance to benefit from novel treatment alternatives, including immune checkpoint blockade and antiangiogenic agents and, given positive trial results, from afatinib, a second generation tyrosine kinase inhibitor (TKI) that irreversibly antagonizes ErbB family tyrosine kinase receptors. Considering the role of the ErbB-signaling cascade in lung SqCC, it is relevant to note that ErbB1 (epidermal growth factor receptor [EGFR]) is overexpressed in 85% of non-small-cell lung carcinomas (NSCLCs), particularly in patients with squamous histology, and is associated with poor prognosis. For this reason, EGFR activity has been investigated as a therapeutic strategy in lung SqCC. Even taking into account statistically positive trial results, anti-EGFR approach still remains controversial in unselected/wild-type EGFR lung SqCC patients, as well as the optimal timing and sequencing of all available targeted therapies considering the approval of immunotherapeutic agents. This review analyzes current data about EGFR inhibition in lung SqCC with a specific focus on afatinib in order to elucidate available clinical evidence supporting EGFR targeting in this setting as well as a future management of advanced lung SqCCs in the context of new emerging immunotherapeutic drugs. Keywords: lung cancer, NSCLC, tyrosine kinase inhibitor, LUX-Lung, EGFR, TKI Vavalà TDove Medical Pressarticlelung cancerNSCLCsquamous cell lung carcinomaafatinibEGFRTKITherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 147-157 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer NSCLC squamous cell lung carcinoma afatinib EGFR TKI Therapeutics. Pharmacology RM1-950
spellingShingle	lung cancer NSCLC squamous cell lung carcinoma afatinib EGFR TKI Therapeutics. Pharmacology RM1-950 Vavalà T Role of afatinib in the treatment of advanced lung squamous cell carcinoma
description	Tiziana Vavalà ASL CN1, SC Oncologia, Ospedale Civile di Saluzzo, Saluzzo, Cuneo, Italy Abstract: Lung cancer treatment has considerably changed over the last few years: the identification of druggable oncogenic alterations and innovative immunotherapic approaches granted lung cancer patients the possibility of more efficient and less toxic therapeutic options than chemotherapy. Nowadays, lung squamous cell carcinomas (SqCCs) patients have the chance to benefit from novel treatment alternatives, including immune checkpoint blockade and antiangiogenic agents and, given positive trial results, from afatinib, a second generation tyrosine kinase inhibitor (TKI) that irreversibly antagonizes ErbB family tyrosine kinase receptors. Considering the role of the ErbB-signaling cascade in lung SqCC, it is relevant to note that ErbB1 (epidermal growth factor receptor [EGFR]) is overexpressed in 85% of non-small-cell lung carcinomas (NSCLCs), particularly in patients with squamous histology, and is associated with poor prognosis. For this reason, EGFR activity has been investigated as a therapeutic strategy in lung SqCC. Even taking into account statistically positive trial results, anti-EGFR approach still remains controversial in unselected/wild-type EGFR lung SqCC patients, as well as the optimal timing and sequencing of all available targeted therapies considering the approval of immunotherapeutic agents. This review analyzes current data about EGFR inhibition in lung SqCC with a specific focus on afatinib in order to elucidate available clinical evidence supporting EGFR targeting in this setting as well as a future management of advanced lung SqCCs in the context of new emerging immunotherapeutic drugs. Keywords: lung cancer, NSCLC, tyrosine kinase inhibitor, LUX-Lung, EGFR, TKI
format	article
author	Vavalà T
author_facet	Vavalà T
author_sort	Vavalà T
title	Role of afatinib in the treatment of advanced lung squamous cell carcinoma
title_short	Role of afatinib in the treatment of advanced lung squamous cell carcinoma
title_full	Role of afatinib in the treatment of advanced lung squamous cell carcinoma
title_fullStr	Role of afatinib in the treatment of advanced lung squamous cell carcinoma
title_full_unstemmed	Role of afatinib in the treatment of advanced lung squamous cell carcinoma
title_sort	role of afatinib in the treatment of advanced lung squamous cell carcinoma
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/837228eaa698435f878962933e6ea4e8
work_keys_str_mv	AT vavalat roleofafatinibinthetreatmentofadvancedlungsquamouscellcarcinoma
_version_	1718400118598664192

Role of afatinib in the treatment of advanced lung squamous cell carcinoma

Ejemplares similares